Ameloblastic Fibrosarcoma of the Mandible With Distant Metastases

Pourdanesh, Fereydoun; Mohamadi, Mansoureh; Moshref, Mohammad; Soltaninia, Omid

doi:10.1016/j.joms.2015.07.003

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with AFS originating from AF have a mean age of 33 years, and those with de novo AFS (previous AF not demonstrated) are one decade younger. AFS usually appears as painful swelling, and paraesthesia may be present[ 5 , 25 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

“…Treatment and prognosis: Because AFS is locally very aggressive, with a high tendency to relapse, treatment includes wide surgical removal and long-term follow-up. Adjuvant radiotherapy has been used in some cases with favorable results[ 29 ], while the usefulness of chemotherapy has not been confirmed[ 26 ]. Recurrence occurs in approximately 20% and metastasis in only 4.5% of cases, but the mortality after 5 years of treatment is relatively high, estimated in 25.4% of cases[ 1 , 25 , 27 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mixed odontogenic tumors: A review of the clinicopathological and molecular features and changes in the WHO classification

Sánchez‐Romero¹,

Almeida²,

Bologna‐Molina³

2021

WJCO

View full text Add to dashboard Cite

BACKGROUND Ameloblastic fibromas and ameloblastic fibrosarcomas are rare odontogenic tumors, and controversy exists in the classification of cases presenting hard-tissue production: Ameloblastic fibrodentinoma (AFD) and ameloblastic fibro-odontoma (AFO). These cases are currently considered “developing odontomas” (hamartomatous lesions). AIM To analyze the clinicopathologic features of these lesions and discuss the changes in the 2017 World Health Organization classification. METHODS An electronic literature search was performed in the PubMed/MEDLINE database. An electronic search of the English language literature was performed and last updated in September 2020 in the PubMed/MEDLINE database using the following terms: “ameloblastic fibroma”, “ameloblastic fibrodentinoma”, “ameloblastic fibro-odontoma”, “ameloblastic sarcoma”, “ameloblastic fibrosarcoma”, “ameloblastic fibrodentinosarcoma”, “ameloblastic fibroodontosarcoma” and “odontogenic carcinosarcoma”. The inclusion criteria were odontogenic tumor series, case reports and systematic reviews that provided sufficient clinical, radiological and microscopic documentation to confirm the diagnosis. RESULTS The database search strategy resulted in 947 papers. Articles focusing on other topics, articles that were not in English, duplicate articles, and articles without fulfilling the inclusion criteria were excluded. Finally, 96 publications were included in this review to describe and discuss the main features of the searched entities. Several aspects of AFO and AFD, such as biological behavior, age of occurrence, amount of hard tissue, and potential for malignant transformation into odontogenic sarcomas, support the neoplastic nature in most of the reported cases. Considering the clinical, radiographic, histopathological and molecular characteristics of odontogenic lesions with hard tissue production, we suggest that these types of lesions should continue to be recognized as odontogenic tumors by maintaining the classically used terms. CONCLUSION This recommendation will be relevant for future clinical, microscopic, and molecular studies to better understand the biology of these interesting odontogenic tumors.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Mixed odontogenic tumors: A review of the clinicopathological and molecular features and changes in the WHO classification

Sánchez‐Romero¹,

Almeida²,

Bologna‐Molina³

2021

WJCO

View full text Add to dashboard Cite

show abstract

“…Chemotherapy with ifosfamide and doxorubicin and corresponding consolidated treatment by re-irradiation has been recommended for AFOS by Gatz et al ( 6 ). However, lung metastases were found in a patient 20 months after surgery and postoperative chemotherapy ( 14 ). Therefore, due to its uncertain benefits, the use of adjuvant radiochemotherapy remains a subject of debate.…”

Section: Discussionmentioning

confidence: 99%

Ameloblastic fibro‑odontosarcoma of the mandible with active epithelial proliferation: A rare case report

et al. 2017

View full text Add to dashboard Cite

Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare subtype of odontogenic sarcoma, with no more than 19 cases reported in the English literature to date. AFOS is a biphasic neoplasm, with deposits of dentin and enamel matrix. We herein present a case of AFOS with active epithelial proliferation in a 31-year-old female patient. The patient was referred to the West China Hospital of Stomatology (Chengdu, China) due to a 6-month history of a swelling in the left mandible. Following clinical and radiological examination, the initial preoperative diagnosis was ameloblastoma, with local invasion and the possibility of malignant transformation. Left hemimandibular resection was subsequently performed. The postoperative histopathological diagnosis was AFOS, accompanied by active epithelial proliferation. Immunohistochemically, cytokeratin (CK)14 and CK19 were intensely positive in the epithelium, whereas the mesenchymal cells were strongly positive for vimentin. The Ki-67 labeling index was considerably higher in the mesenchymal component (mean, 40%) compared with that in the epithelial element (mean, 5–8%). Three months after the surgical procedure, the patient remained clinically and radiologically disease-free.

show abstract

“…It should be mentioned that clinical and surgical aspects of this case have been discussed before in the literature. [ 9 ]…”

Section: Introductionmentioning

confidence: 99%

A mixed odontogenic sarcoma: A challenging histopathologic case and brief review of the literature

Atarbashi-Moghadam

Lotfi

Mokhtari

2018

J Oral Maxillofac Pathol

View full text Add to dashboard Cite

Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare malignant mixed odontogenic tumor. The ectomesenchymal part of the neoplasm shows malignancy, whereas the epithelial component is rather benign. In addition, small areas with deposition of enamel matrix and dentine material are seen. The rarity of this neoplasm and microscopic similarities with other malignant and benign tumors can lead to diagnostic problems. Here, we describe the histopathologic features of a new case of AFOS of the mandible in a 34-year-old female patient. It is essential for oral pathologists to be familiar with the microscopic features of this rare neoplasm to have a proper diagnosis. This is also the first reported case of AFOS that closely resembles osteosarcoma in some areas.

show abstract

Ameloblastic Fibrosarcoma of the Mandible With Distant Metastases

Cited by 7 publications

References 12 publications

Mixed odontogenic tumors: A review of the clinicopathological and molecular features and changes in the WHO classification

Mixed odontogenic tumors: A review of the clinicopathological and molecular features and changes in the WHO classification

Ameloblastic fibro‑odontosarcoma of the mandible with active epithelial proliferation: A rare case report

A mixed odontogenic sarcoma: A challenging histopathologic case and brief review of the literature

Contact Info

Product

Resources

About